Avicanna Inc. (AVCNF)

Market Cap	21.41M
Revenue (ttm)	18.60M
Net Income (ttm)	-1.03M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,500
Average Volume	93,834
Open	0.1860
Previous Close	0.1855
Day's Range	0.1825 - 0.1871
52-Week Range	0.1150 - 0.3145
Beta	0.38
RSI	40.64
Earnings Date	Nov 11, 2025

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of de...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 87
• Stock Exchange: OTCMKTS
• Ticker Symbol: AVCNF

Financial Performance

In 2024, Avicanna's revenue was 25.46 million, an increase of 51.62% compared to the previous year's 16.79 million. Losses were -3.62 million, -58.62% less than in 2023.

Financial numbers in CAD